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Abstract
Background—The CpG Island Methylator Phenotype (CIMP) is a major molecular pathway in 
colorectal cancer (CRC). Approximately 25% to 60% of CIMP tumors are microsatellite unstable 
(MSI-H) due to DNA hypermethylation of the MLH1 gene promoter. Our aim was to determine if 
the distributions of clinicopathologic factors in CIMP-positive tumors with MLH1 DNA 
methylation differed from those in CIMP-positive tumors without DNA methylation of MLH1.
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Methods—We assessed the associations between age, sex, tumor-site, MSI status BRAF and 
KRAS mutations and family CRC history with MLH1 methylation status in a large population-
based sample of CIMP-positive CRCs defined by a 5-marker panel using unconditional logistic 
regression to assess the odds of MLH1 methylation by study variables.
Results—Subjects with CIMP-positive tumors without MLH1 methylation were significantly 
younger, more likely to be male, more likely to have distal colon or rectal primaries and the MSI-
L phenotype. CIMP-positive MLH1-unmethylated tumors were significantly less likely than 
CIMP-positive MLH1-methylated tumors to harbor a BRAF V600E mutation and significantly 
more likely to harbor a KRAS mutation. MLH1 methylation was associated with significantly 
better overall survival (HR=0.50; 95% Confidence Interval (0.31, 0.82)).
Conclusions—These data suggest that MLH1 methylation in CIMP-positive tumors is not a 
completely random event and implies that there are environmental or genetic determinants that 
modify the probability that MLH1 will become methylated during CIMP pathogenesis.
Impact—MLH1 DNA methylation status should be taken into account in etiologic studies.
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Introduction
There are multiple molecular phenotypes of colorectal cancer (CRC) (1). The CpG Island 
Methylator Phenotype (CIMP) is one of these, present in about 15% of CRCs and 
characterized by widespread aberrant DNA hypermethylation across the genome of cancer 
cells (2–6). About 25% to 60% of CIMP-positive tumors, depending on the study 
population, display high levels of microsatellite instability (MSI-H), mainly due to 
transcriptional silencing of the MLH1 DNA mismatch repair gene by somatic DNA 
methylation of the MLH1 gene promoter region (4–7). Studies of multiple populations, 
including the current study population (8, 9), have reported that somatic MLH1 DNA 
methylation is associated with several clinicopathological variables including older age, 
female gender, proximal tumor location and the BRAF V600E mutation (reviewed in (10)). 
These differences have been defined in comparisons of CIMP-positive to CIMP-negative 
tumors. However, there is much less data on the comparison of MLH1 methylated to MLH1 
unmethylated tumors within the CIMP-positive tumor subset. We are aware of only one 
study comparing CIMP-positive MLH1 unmethylated to CIMP-positive MLH1 methylated 
tumors and this small study was limited to MSI-H tumors (11).
DNA methylation of the MLH1 promoter region, reported in 22% to 49% of CIMP-positive 
tumors (6, 11–13), is a key event for determining CRC phenotype for two reasons. First, the 
methylation-induced loss of MLH1 protein expression is likely to be the underlying cause 
for somatically altered MSI-H tumors, given that the methylation is predominantly 
associated with loss of its protein expression. Second, the methylation of the MLH1 
promoter almost always occurs in the context of CIMP (5, 6, 14, 15) and, therefore, may 
also be a consequence of the same pathogenetic mechanisms that are most commonly 
associated with CIMP. Given this, a key question is whether or not the MLH1 methylation is 
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a random event unrelated to the presence of one or more risk factors, for example age or sex, 
in which case future etiologic studies of CIMP can ignore MLH1 methylation status. 
Alternatively, if there are distinct risk factors within CIMP-positive tumors, these studies 
will need to consider MLH1 methylation status in the analysis.
In the present analysis we assessed the correlations between MLH1 promoter region DNA 
methylation and age, sex, tumor site and MSI status, as well as BRAF and KRAS mutations 
and family history of CRC, in a large population-based sample of CIMP-positive colorectal 
tumors. We reasoned that if the probability that the MLH1 promoter-region DNA becomes 
methylated during CIMP pathogenesis is due solely to a random process within CIMP 
pathogenesis there will be no differences between the MLH1 unmethylated and MLH1 
methylated tumors in the genetic or environmental CIMP-associated factors (e.g. age, sex 
and tumor location) while the different phenotypes (MSS v MSI-H) will affect pathological 
findings (e.g. infiltrating lymphocytes or signet ring cells) in the two tumor subsets. Finally, 
we assessed overall survival in CIMP-positive tumors by MLH1 methylation status, in 
general and stratified by the presence of BRAF and KRAS mutations. No tested tumors 
classified as CIMP-negative were included in the analysis. We did not assess pathologic 
characteristics of the tumors because it is likely that many of these are consequences rather 
than causes of the MSI-H phenotype.
Materials and Methods
Subjects
Data for this study were obtained through the Colon Cancer Family Registry (C-CFR), a 
National Cancer Institute funded registry of CRC cases, family members and population-
based controls, which utilized standardized methods for data collection and genotyping. 
Detailed information about the C-CFR can be found elsewhere (16) and at coloncfr.org. 
Recruitment at individual C-CFR sites has been described previously (16). Participants were 
recruited from six C-CFR centers: the University of Southern California (USC) Consortium 
(Arizona, Colorado, New Hampshire, Minnesota, North Carolina, and Los Angeles, 
California), the University of Hawaii (Honolulu), Fred Hutchinson Cancer Research Center 
(FHCRC, Seattle, WA), Mayo Clinic (Rochester, MN), Cancer Care Ontario (Toronto, 
Canada), and University of Melbourne (Victoria, Australia) using population-based 
ascertainment strategies. All centers except FHCRC oversampled case probands with first-
degree relatives reporting CRC, or CRC case probands diagnosed under age 50 to target 
families with increased CRC risk. Over 80% of recruited subjects were Caucasian. We used 
sampling weights that reflected the sampling probability that the case proband was recruited 
into the registry, accounting for family history, age and race, relative to the base population. 
First-degree and some second-degree relatives with CRC were also recruited from families 
with multiple CRC cases. In this study, we included only CRC cases recruited from 1997– 
2002 (16). Each institution’s Institutional Review Board (IRB) approved the study protocol 
and all subjects signed a written informed consent approved by their IRB. Only subjects who 
completed the risk factor questionnaire (RFQ) within 5 years of their CRC diagnosis were 
included.
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Tumor blocks
Primary CRC formalin-fixed, paraffin-embedded (FFPE) tissue from the Jeremy Jass 
Memorial Tissue Bank was collected and processed as previously described (9). Briefly, we 
requested blocks from all population-based case probands recruited in 1997–2002 as well as 
their colorectal cancer–affected first-, second-, and third degree relatives. This totaled 3,970 
specimens, out of which we received 3,732 (94%) sets of slides. Specifically, we received 
two unstained 5-mm tissue sections embedded in paraffin from each tumor on positively 
charged "plus" glass slides without coverslips. Slides were microdissected to enrich for 
tumor cells and DNA was extracted as described (17). Proteinase K was inactivated by 
heating at 100° C for 10 minutes. Tissues were randomized before being analyzed.
CIMP determination
The method for CIMP analysis is described in detail in Weisenberger et al. (9): Briefly, all 
samples were bisulfite converted using the Zymo EZ-96 DNA methylation kit (Zymo 
Research, Irvine, CA) as specified by the manufacturer. The DNA methylation levels of 
individual loci were assessed using MethyLight technology as described (9). CIMP status in 
each sample was determined using a five-gene MethyLight-based signature (CACNA1G, 
IGF2, NEUROG1, RUNX3 and SOCS1) described previously (6). All MethyLight CIMP 
assays were performed using a control reaction specific for Alu repeats as a means of 
normalizing for input bisulfite DNA amounts. MethyLight data were organized as percent of 
methylated reference (PMR) value. Genes were considered methylated if the PMR value 
was ≥ 10. Tumors with methylation in ≥ 3 of these 5 genes were classified as CIMP-
positive. Those with 2 or fewer methylated genes were considered CIMP-negative and 
excluded from this analysis. Out of the 3,732 samples processed, 46 (1.2%) failed the assay. 
MLH1 methylation status was determined using the MLH1-M2 MethyLight assay as 
previously described (6) and classified as methylated for PMR ≥ 10.
Risk factors
We obtained risk factor data (age, sex and family CRC history) from the completed baseline 
risk factor questionnaire (RFQ) available at coloncfr.org. Age at the time of enrollment was 
categorized as a three-category variable: ≤ 50, 51–69 and ≥ 70 years. Family history of CRC 
was self-reported and was considered positive if the case reported CRC in one or more first-
degree family members (e.g. parents, siblings or children).
Tumor site
Tumor site was abstracted from pathology reports and/or state or provincial cancer registries 
and coded using International Classification of Diseases for Oncology (ICD-O), third edition 
codes. Tumors were labeled as proximal colon if located in the cecum, ascending colon, 
hepatic flexure, transverse colon and splenic flexure. Tumors were labeled as distal colon if 
located in the descending colon, sigmoid colon and tumors overlapping the colon and 
rectum. Tumors were labeled as rectal if located in the rectum or rectosigmoid junction.
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KRAS and BRAF Mutation testing
DNA from each tumor sample was tested for BRAF and KRAS mutations. The somatic T>A 
mutation at nucleotide 1799 causing the p.V600E mutation in BRAF was determined using a 
fluorescent allele-specific PCR assay that amplified a 97bp product for the mutant allele 
(A1799) and a 94bp product for the wildtype allele (T1799), as previously described (18). 
Positive controls were run in each experiment and 10% of samples were replicated with 
100% concordance. KRAS mutation analysis of codons 12 and 13 was performed using 
direct Sanger sequencing of a 169bp PCR amplified product as previously described (19). 
The larger amplicon size for KRAS analysis compared with BRAF V600E contributed to a 
slightly higher proportion of samples failing to amplify for the KRAS assay compared with 
BRAF V600E assay.
MSI testing
MSI was tested using DNA from tumor and matched normal tissue as described in (20) 
using 10 microsatellite loci (BAT25, BAT26, BAT40, BAT34C4, D5S346, D17S250, 
ACTC, D18S55, D10S197, and MYCL). Samples were classified as MSI-H if > 30% 
showed instability, MSS if no markers showed instability and MSI-L otherwise. Tumor 
classification was based on ≥4 interpretable markers.
MMR gene mutation carriers
Identification of individuals with germline MMR gene mutations was determined for MSI-H 
tumors as previously described (21, 22). Briefly, all tumors with a missing mismatch repair 
protein by immunohistochemistry were tested for germline mutations in the corresponding 
mismatch repair gene. MLH1, MSH2 and MSH6 mutations were identified using Sanger 
sequencing or denaturing high performance liquid chromatography (dHPLC), followed by 
confirmatory DNA sequencing. Large duplication and deletion mutations including those 
involving EPCAM, were detected by Multiplex Ligation Dependent Probe Amplification 
(MLPA) according to the manufacturer’s instructions (MRC Holland, Amsterdam, The 
Netherlands). PMS2 mutations were identified as previously described (22, 23) where exons 
1–5, 9 and 11–15 were amplified in three long range PCRs followed by nested exon specific 
PCR/sequencing. The remaining exons (6, 7, 8 and 10) were amplified and sequenced 
directly from genomic DNA. Large-scale deletions in PMS2 were detected using the P008-
A1 MLPA kit according to manufacturer’s specifications (MRC Holland, Amsterdam, The 
Netherlands). Eight individuals with germline MMR gene mutations were identified in the 
data set, one of which was CIMP-positive and excluded from the analysis.
Statistical Analyses
All analyses included only tumors tested and classified as CIMP. No tested tumors classified 
as non-CIMP were included. Contingency tables and Chi-Square analysis were used to 
assess the prevalence of patient and tumor characteristics in CIMP-positive tumors by 
MLH1 methylation status. Unconditional logistic regression was used to compare tumor 
subsets while mutually controlling for all studied variables except for MSI status, which was 
too highly associated with MLH1 methylation to estimate an odds ratio. Pearson correlation 
coefficients were used to assess correlations between the raw PMR values of the CIMP 
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markers. All analyses were weighted based on the inverse of the sampling probability that 
the case proband was recruited into the registry to ensure the numbers represent the entire 
population of CRC cases at each study site. Subjects were included from all C-CFR sites 
except Hawaii, because their sampling design precluded this type of weighted analysis. 
Frequencies are based on the weighted number of tumors in each category.
Overall Survival
We used Cox proportional hazards regression to evaluate the association between MLH1 
methylation status and overall survival among individuals with CIMP-positive CRC, 
accounting for sampling weights, using time since diagnosis as the time axis. Survival 
analyses were adjusted for age, sex, tumor site (proximal vs distal/rectal) and family history 
of CRC in at least one first-degree relative (yes, no); analyses were further adjusted for 
study site via stratification of the baseline hazards. Including tumor stage in the model did 
not modify the results. In addition to this primary analytic model, we conducted sensitivity 
analyses adjusting for MSI, BRAF and KRAS mutation status as well as analyses stratifying 
on these tumor attributes.
For all analyses statistical significance was defined as a p-value ≤ 0.05 in a two-sided test. 
Statistical analyses for the clinicopathologic variables (age, sex, tumor site, MSI status, 
family CRC history and BRAF and KRAS mutations) were performed using SAS 9.3 (SAS 
institute Inc., Carey, NC) and the survival analysis was conducted using Stata 13 (Stata 
Corp., College Station, TX).
The processed samples yielded a total of 3,660 CRCs with CIMP classification: 3,544 
primary CRCs from case probands and 116 CRCs from affected relatives. Of these primary 
CRCs, 108 case probands (3.0%) were excluded for having been interviewed more than 5 
years after diagnosis, 203 (5.7%) for missing RFQ data, and 104 (2.9%) for missing tumor 
site data or sampling weights. The final data set included 3,119 (unweighted) primary CRCs 
from case probands, 411 (unweighted) of which were classified as CIMP-positive and 
included in this analysis. After applying the sampling weights and deleting one proven 
Lynch Syndrome subject a total of 786 tumors were included in the analysis.
Results
The overall risk factor distribution and prevalence of DNA methylation for the five CIMP 
markers and MLH1 for all CIMP-positive tumors included in this analysis is presented in 
Table 1. Over 90% of the CIMP-positive study population was older than age 50 and 59% 
were female. Eighty one percent (81%) of all CIMP-positive tumors were in the proximal 
colon and approximately half were MSI-H. BRAF and KRAS mutations were present in 62% 
and 18% of tumors respectively and 19% of all subjects reported a history of CRC in one or 
more first degree relatives. MLH1 was methylated in 51% of CIMP-positive tumors.
We next determined the associations between clinicopathologic factors and MLH1 
methylation status in both univariate and multivariate analyses (Table 2). In univariate 
analysis, MLH1 unmethylated tumors occurred significantly more often in those under 50 
years of age at diagnosis, in men, and in distal and rectal tumors (all p-values <0.0001). 
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Individuals with MLH1 unmethylated tumors were significantly less likely to report a CRC 
diagnosis in a first-degree relative (P=0.0226). Overall, 7.5% of MLH1 unmethylated tumors 
were also MSI-H. In addition, MLH1 unmethylated tumors were significantly more likely 
than tumors with MLH1 methylation to be classified as MSI-L (20.7% compared to 0.25% 
respectively; P<0.0001). CIMP-positive tumors with MLH1 methylation were mainly 
classified as MSI-H (98%), as expected. Tumors without MLH1 methylation were 
significantly less likely to have a BRAF V600E mutation than MLH1 methylated tumors 
(42.3% versus 86.2% respectively; P <0.0001) and were more likely to have a mutation in 
KRAS codon 12 or codon 13 (39.5% versus 2.1% respectively; P<0.0001). Including MLH1 
in the panel defining CIMP status did not change any results (39.5% mutated versus 3.0% 
mutated respectively). Except for family CRC history, these associations were not altered in 
a multivariate analysis mutually controlling for all the variables except for MSI status. The 
odds ratio (OR) for family CRC history was essentially null after multivariate adjustment. 
There was a low to moderate correlation between the PMR’s of all markers with MLH1 
methylation and each other. The correlation coefficients ranged from 0.017 to 0.48.
Table 3 shows the association between MLH1 methylation and overall survival in 
multivariate analyses. Patients with CIMP-positive, MLH1 DNA methylated tumors were 
50% less likely to die during the observation period of up to 15 years in univariate analysis 
(Hazard Ratio (HR) = 0.50 (95% Confidence Interval (CI) = 0.31, 0.82)). This association 
was no longer significant after adjustment for MSI status, but the point estimate did not 
change materially. Adjustment for BRAF or KRAS mutation status also did not substantially 
change the estimates. In stratified analyses, the HR associated with MLH1 methylated status 
was significantly decreased only for cases with a mutated BRAF (HR=0.41 (95% CI=0.22, 
0.77) or a wild-type KRAS (HR=0.46 (95% CI=0.25, 0.84)).
Discussion
In this large population-based sample MLH1 methylation in CIMP-positive tumors was 
associated with the characteristics commonly observed for MSI-H and CIMP-high tumors 
relative to non-CIMP tumors (10). CIMP positive MLH1-unmethylated tumors were more 
prevalent in men, and significantly more common in younger age groups and in distal 
tumors than CIMP positive, MLH1-methylated tumors. The prevalence of BRAF and KRAS 
mutations also differed significantly between the MLH1 unmethylated and MLH1 
methylated tumors.
Overall, our results are consistent with those of other studies. Kim et al. observed a highly 
significant difference in the sex ratio in individuals with CIMP-positive, MLH1 methylated 
tumors (55% female) compared to individuals with CIMP-positive tumors where MLH1 was 
unmethylated (9% female), in a Korean population (11). An increase in the prevalence of 
distal tumors among those without MLH1 methylation compared to those with MLH1 
methylation was also seen in that study, as well as a significantly lower prevalence of BRAF 
mutation and higher prevalence of KRAS mutations in unmethylated tumors, as we observed 
here. However, all tumors were MSI-H in that study and the prevalence of Lynch Syndrome 
in the small set of CIMP-positive MLH1 unmethylated tumors was not provided. Similar 
differences were observed in studies comparing CIMP/MSI-H tumors (as a proxy for MLH1 
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DNA methylation) to non-CIMP tumors (4, 7, 24) and studies that assessed risk factors for 
MLH1 DNA methylation in CIMP-positive tumors compared to non-CIMP tumors (12, 25).
The different age distributions in subjects with MLH1 unmethylated tumors compared to 
those with a MLH1 methylated tumor suggests a role for age-associated epigenetic drift as a 
factor promoting MLH1 methylation in our study population (26, 27). A positive association 
between age and MLH1 DNA methylation has been reported (28, 29). Looking only at 
CIMP-positive MLH1 methylated or CIMP-positive MSI-H tumors, an association between 
MLH1 methylation or MSI-H and older age was observed in multiple studies (4, 7, 11, 30) 
supporting this conclusion.
A preponderance of females in CIMP-positive tumors is not a universal finding. Several 
studies report a higher CIMP prevalence in male subjects (13, 31–34) as we observed for the 
CIMP-positive, MLH1 unmethylated tumors in our population. It may be significant that 
four of these five studies were of Asian populations. Additionally, in a previous analysis of 
this population, we observed that several risk factors for a CIMP positive tumor were 
significantly associated with a CIMP-positive tumor only among females (9). Taken 
together these data suggest that female sex is a proxy for more biologically relevant 
exposures that vary between populations.
Several previous studies of potential CIMP markers have reported that there may be more 
than one type of CIMP-positive tumor (35–40). In these studies, using significantly more 
marker genes, tumors designated as CIMP could be further differentiated statistically into a 
CIMP-Low/CIMP2/Intermediate (IME) or low methylation (LME) group and a CIMP-High/
CIMP1/High methylation (HME) group with different marker gene sets. Tumors classified 
as CIMP-Low were significantly more likely to be MSS and have a KRAS mutation in these 
populations compared to tumors classified as CIMP-High. This is similar to what we 
observed in our data after stratifying on MLH1 methylation alone, even though all tumors 
used in this analysis were classified as CIMP-positive using a marker panel for what is 
variably called CIMP-H (35, 37, 39), CIMP1 (38) or HME (36, 40). We note that MLH1 
methylation status was not a criterion for establishing CIMP status in the current and other 
analyses (35, 38, 39). However, redefining CIMP status using a 6 marker panel that included 
MLH1 methylation did not change any of the observed associations. Future studies are 
required to assess directly whether MLH1 methylation is associated with CIMP-Low or if 
different types of CIMP tumors must be identified using separate marker panels.
Establishing that a tumor has an MSI-H phenotype has important prognostic value (41) and 
may also be predictive of treatment response (42). Data from a meta-analysis concluded that 
the MSI-H phenotype, due mainly to MLH1 methylation, is associated with a better 
prognosis than tumors with the MSS phenotype (41) so identifying the two different types of 
CIMP-positive tumors, those in which the MLH1 promoter region DNA is not methylated 
(MSS), and those with MLH1 methylation (MSI-H) may be of clinical relevance. In a recent 
meta-analysis CIMP was associated with a bad prognosis in both MSI-H and MSS tumors 
(43). In our data, using only CIMP-positive tumors, overall survival was decreased in those 
without MLH1 methylation compared to those with MLH1 methylation. This is consistent 
with the close association between MLH1 methylation and MSI-H and the reduction in 
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significance after controlling for MSI status. However, in our population, the better 
prognosis was limited to subjects with a tumor that was KRAS-wildtype, most of whom also 
had tumors that were BRAF-mutated. The presence of the BRAF V600E mutation was 
associated with a poor prognosis overall in a meta-analysis (44) while data from several 
studies suggest that the poor prognosis may be ameliorated by the presence of MSI-H (45–
49). In one of those studies survival was significantly better in MSI-H, BRAF mutated 
tumors relative to MSS, BRAF wild type tumors (46). Reaching a consensus about the 
modifying effect of BRAF mutation on prognosis in CIMP-positive MLH1 methylated 
tumors will require further study.
The strengths of our study include the facts that it is the largest study to date of CIMP-
positive CRC tumors and that we utilized a population-based sample weighted for age, race 
and family history so that our results can be generalized. We limited the current analysis to 
CIMP positive tumors so that unmeasured causal factors were equally relevant for both 
unmethylated and methylated tumors and there can be no confounding by differential effects 
of unmeasured exposures relevant mainly to non-CIMP tumors. Our study also has some 
weaknesses. Although we used a set of well-characterized markers to define CIMP status (6) 
an eight marker CIMP panel has been described (3) which may have eliminated some 
tumors from this analysis had it been used instead (50). Alternatively, some CIMP tumors in 
the parent data set may not have been identified as CIMP using our marker panel and so 
were wrongly excluded from the analysis. Additionally, it is possible that some MLH1 
unmethylated tumors should have been classified as CIMP-Lo as discussed above. It is 
unclear how this misclassification may have biased the results. Studies using genome-wide 
methylation techniques to improve CIMP classification, which we were unable to do, may 
decrease this type of misclassification in the future. Our assay for MLH1 methylation was 
limited to 8 CpG sites in the previously described C region of the promoter (51) which 
might have caused us to misclassify some methylated tumors as unmethylated, biasing our 
results toward null values. We were unable to control for MSI status in our multiple 
regression analysis due to the small number of MLH1-methylated MSS tumors so there may 
be residual confounding by this variable in the multivariate OR’s. It is unclear how this may 
have biased our adjusted OR’s. KRAS mutation data was missing for 16% of tumors, 
although approximately equally in MLH1 methylated (15.2%) and unmethylated subsets 
(17%), and we only looked at KRAS mutations in codons 12 and 13. Thus, our data for 
KRAS mutations may be biased toward the null value. Finally, we were not able to assess or 
control for the association between MLH1 methylation and the MLH1 -93GA genotype 
(rs1800734) because only about 25% of the study population was genotyped for that SNP.
In conclusion, our analysis suggests that there are significant differences between CIMP-
positive tumors with MLH1 DNA methylation and CIMP-positive tumors without such 
methylation for variables classically associated with CIMP. The differences included 
exposures (e.g. age, sex and tumor site) which cannot be consequences of the CIMP 
phenotype. These results, in the context of data from other populations, are consistent with 
the hypothesis that MLH1 methylation in CIMP-positive tumors is not a completely random 
event and implies that there are environmental or genetic determinants that modify the 
probability that MLH1 will become methylated during CIMP pathogenesis. This suggests 
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that etiologic studies of the CIMP pathway may need to stratify on MLH1 methylation 
status.
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Table 1
Characteristics of the study population with CIMP-positive1 cancers
Weighted N2 Prevalence (%)
Age
  <50 52 6.6
  51–69 406 51.6
  ≥ 70 329 41.8
Sex
  Male 322 41.0
  Female 464 59.0
Tumor Site3
  Proximal 636 80.9
  Distal 83 10.5
  Rectal 68 8.6
MSI status4
  MSS 280 35.6
  MSI-L 81 10.3
  MSI-H 424 53.9
Missing 2 0.25
BRAF mutation
  Present5 490 62.3
  Absent 274 34.8
Missing 22 2.9
KRAS mutation
  Present6 138 17.6
  Absent 520 66.2
Missing 128 16.3
Family History7
  No 632 80.3
  Yes 149 18.9
Missing 6 0.76
N methylated:
  CACNA1G 619 78.7
  IGF2 737 93.8
  NEUROG1 781 99.4
  RUNX3 693 88.2
  SOCS1 429 54.6
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Weighted N2 Prevalence (%)
  MLH1 402 51.2
1
Defined as a PMR ≥10 for at least 3 of 5 genes: CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1.
2As defined in the text the sampling weights are the inverse of the sampling fraction which corrected for the oversampling of case probands by age, 
race and family history. N’s are rounded to the nearest whole number.
3
Tumors were labeled as ascending colon if located in the cecum through the splenic flexure. Tumors were labeled as distal colon if located in the 
descending colon through the sigmoid colon and included tumors ‘overlapping the colon and rectum.’ Tumors were labeled as rectal if located in 
the rectum or rectosigmoid junction.
4
MSI status was determined using 10 microsatellites as described in the text.
5
Presence of the BRAF V600E mutation.
6
Presence of either a codon 12 or codon 13 KRAS mutation.
7
Defined as a Self-reported history of CRC in at least one 1st degree relative.
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Table 3
Association of MLH1 methylation1 in CIMP-positive2 CRC’s with overall survival3 after CRC diagnosis*
Analysis Unweighted
N(deaths)
Weighted N
(deaths)
HR (95% CI)
Overall Survival (baseline analysis4) 390 (162)
  MLH1 unmethylated 188 (92) 371 (168)
  MLH1 methylated 202 (70) 374 (118) 0.50 (0.31, 0.82)
Additionally controlling for MSI status 0.47 (0.20, 1.08)
Additionally controlling for BRAF5 mutation status 0.49 (0.28, 0.86)
Additionally controlling for KRAS6 mutation status 0.50 (0.28, 0.87)
Additionally controlling for joint BRAF and KRAS status 0.51 (0.28–0.91)
In BRAF mutated cases 250 (97) 465 (179) 0.41 (0.22, 0.77)
In BRAF wild-type cases 136 (62) 269 (103) 0.88 (0.39–1.99)
Missing BRAF status 4 (3)
In KRAS mutated cases 64 (28) 137 (52) 1.35 (0.29, 6.33)
In KRAS wild-type cases 265 (113) 499 (193) 0.46 (0.25, 0.84)
Missing KRAS status 61 (21)
BRAF mutated/KRAS wildtype 209 (87) 392 (153) 0.41 (0.21, 0.79)
BRAF wildtype/KRAS mutated 63 (28) 135 (52) 3.60 (0.98, 13.23)
BRAF wildtype/KRAS wildtype 55 (25) 106 (39) 0.35 (0.13, 0.91)
*
Excludes 21 cases with missing information on date of diagnosis or death.
1
MLH1 methylation was defined as a PMR ≥ 10 using MethyLight analysis as defined in the text.
2
Defined as a PMR ≥10 for at least 3 of 5 genes: CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1.
3
Median follow-up from time since diagnosis was 10 years (range 5 months – 15 years). Overall survival was estimated using a Cox proportional 
hazards regression.
4
Baseline analysis adjusted for age, sex, tumor site (proximal vs. distal/rectal) and family history of CRC in at least one 1st degree relative (yes, 
no). Stratification factors were as identified in column one of the table.
5
Presence of the BRAF V600E mutation.
6
Presence of either a codon 12 or codon 13 KRAS mutation.
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